Furthermore, given involvement of the Lck/NF-kB signalling pathway in cancer cell signalling and in T cell function, blocking over-activation of NF-kB by inhibiting Lck has been suggested for the treatment of both inflammatory disorders and malignancies [66]. Here, NFKB1 is linked to cancer.